August 18, 2014 | Jason Bloomberg speaks to pharma executives and industry observers who believe top drug companies could soon focus more of their efforts on creating electronic health platforms, collecting user data and to more precisely define disease risks and personalize prevention and treatment. While most contributors seem to agree that these platforms could support the sale of therapeutics, some also see this model as a radical break from the traditional drug business. As Joseph Jimenez, CEO of Novartis, tells Bloomberg, “I really believe that in the future, companies like Novartis are going to be paid on patient outcomes as opposed to selling the pill.” Forbes